Loading
A phase 3 trial of Temozolomide and Pembrolizumab in glioma & glioblastoma, run by NovoCure GmbH, now recruiting.
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma is a phase 3 interventional study registered as NCT06556563 by NovoCure GmbH, with 741 participants planned, started 2025-02-03 and due to reach its primary completion in 2029-04. Interventions recorded: Optune® device, Temozolomide, Pembrolizumab and Placebo.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Pembrolizumab and the tag pipeline.
Shares Glioma & glioblastoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.